Objectives: Early diagnosis of cancer remains a great challenge in the field of laboratory medicine. We investigated the ability of ccf DNA and DNA integrity index (DNA II) in differentiating benign from malignant breast diseases.
Methods: Serum samples were collected from 50 patients with benign breast disease (BBD) and 50 newly diagnosed breast cancer (BC) patients, in addition to 50 control women. VEGF was measured by ELISA, while Real-time q-PCR was used to measure ccf DNA concentrations and to assess the concentrations of ALU repeats, both short fragments (115 bp) and long fragments (247 bp), then DNA II was calculated (all were done before and after radical mastectomy).
Results: BC group showed significantly higher ccf DNA concentrations and DNA II compared to BBD and control groups, meanwhile, no statistically significant differences were found between BBD and control groups. Ccf DNA concentrations decreased significantly after surgery (P <0.001). Good AUC was found for ccf DNA (AUC=0.860), fair AUC was found for DNA II (AUC=0.727), while VEGF AUC failed to discriminate between BBD and BC cases.
Conclusion: ccf DNA and DNA II could be used as excellent molecular biomarkers for early diagnosis of BC and for monitoring the efficiency of therapy in such patients. Utilizing these molecular markers would improve both the healthcare and economic burden of malignancy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272613 | PMC |
| http://dx.doi.org/10.31557/APJCP.2022.23.2.545 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Highly-multiplex detection of plasma cell-free human papillomavirus-16 DNA in oropharyngeal carcinoma.
J Clin Virol
January 2025
Center for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address:
Background: Plasma cell-free Human Papillomavirus DNA (cfHPVDNA) is a biomarker for oropharyngeal carcinoma. Existing diagnostics may be limited by inadequate sensitivity or high cost/complexity for longitudinal monitoring.
Objectives: We hypothesized that sensitive and specific plasma cfHPVDNA detection may be achieved via a highly-multiplex qPCR method.
Early detection of colorectal cancer using aberrant circulating cell-free mitochondrial DNA fragmentomics.
Gut
December 2024
Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xi'an, China
Background: Early detection of colorectal cancer (CRC) is crucial for improving the survival rates of patients.
Objective: We aimed to develop a novel strategy for early CRC detection using the fragmentomic features of circulating cell-free mitochondrial DNA (ccf-mtDNA).
Design: Here, a total of 1147 participants, including 478 healthy controls (HCs), 112 patients with advanced adenomas (AAs) and 557 patients with CRC, were enrolled from five hospitals and plasma samples were collected for capture-based ccf-mtDNA sequencing.
Biological Age Acceleration and Colonic Polyps in Persons under Age 50.
Cancer Prev Res (Phila)
December 2024
Sylvester Comprehensive Cancer Center, Miller School of Medicine at the University of Miami, Miami, Florida.
Epigenetic clocks can quantify DNA methylation by measuring the methylation levels at specific sites in the genome, which correlate with biological age (BA). Accelerated aging, where BA exceeds chronologic age, has been studied in relation to cancer development, but its utility in cancer prevention remains unclear. Accelerated aging holds promise as a tool to explain the increase in early-onset colorectal cancer (EOCRC).
View Article and Find Full Text PDFClusterin Deficiency Promotes Cellular Senescence in Human Astrocytes.
Mol Neurobiol
December 2024
Department of Physiology, Faculty of Science, Charles University, Prague, 128 00, Czech Republic.
Article Synopsis
- - The study focuses on the glycoprotein clusterin (CLU), which is important for cell growth and repairing DNA, and its effects on human astrocytic cell lines, showing that suppressing CLU leads to decreased cell growth and increased DNA damage response.
- - Researchers found that reducing CLU levels caused oxidative stress and triggered cellular aging (senescence) in astrocytoma cells and normal astrocytes, impacting mitochondrial function and altering energy production markers.
- - The findings highlight the crucial role of CLU in maintaining the cell cycle in astrocytes, suggesting that targeting CLU could be a promising strategy for treating gliomas (a type of brain tumor).
UBA1 inhibition sensitizes cancer cells to PARP inhibitors.
Cell Rep Med
December 2024
Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Quantitative and Computational Biosciences Program, Baylor College of Medicine, Houston, TX, USA.
Therapeutic strategies targeting the DNA damage response, such as poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), have revolutionized cancer treatment in tumors deficient in homologous recombination (HR). However, overcoming innate and acquired resistance to PARPi remains a significant challenge. Here, we employ a genome-wide CRISPR knockout screen and discover that the depletion of ubiquitin-activating enzyme E1 (UBA1) enhances sensitivity to PARPi in HR-proficient ovarian cancer cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!